OneSource Specialty Pharma Ltd
ONESOURCE NSE
OneSource Specialty Pharma Ltd
HealthcareNSE: ONESOURCE BSE: 544292 Pharmaceuticals & Biotechnology
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics[1]
AI Verdict: SELL Confidence: 7%
OneSource Specialty Pharma trades at a negative PE of -256.3x with consistently negative ROE of -2.39% over 3 years, high promoter pledge of 38.4%, and deteriorating profitability (TTM profit growth of -161%). Despite strong historical sales CAGR of 232% over 3 years, the company fails to convert revenue into sustainable profits.
Key Fundamentals
SmallcapPharmaceuticalsHealthcareMarket Cap
₹18,073 Cr
Volatility
Moderate
P/E Ratio
-242.7
EBITDA
₹294 Cr
Debt to Equity
0.21
Book Value
₹508.64
52W High
₹2,231.9
52W Low
₹1,057
Technical Indicators
Key Insights
Weaknesses
5- Stock is trading at 3.07 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.39% over last 3 years.
- Promoters have pledged 38.4% of their holding.
- Company has high debtors of 177 days.
Growth Rate
Revenue Growth
-2.78% ↘
Net Income Growth
444.34% ↗
Cash Flow Change
36.71% ↗
ROE
-99.69% ↗
ROCE
-103.78% ↗
EBITDA Margin (Avg.)
-38.10% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 3d agoSELL
Risk high
OneSource Specialty Pharma trades at a negative PE of -256.3x with consistently negative ROE of -2.39% over 3 years, high promoter pledge of 38.4%, and deteriorating profitability (TTM profit growth of -161%). Despite strong historical sales CAGR of 232% over 3 years, the company fails to convert revenue into sustainable profits.
Bull Case 7
- Compounded sales growth of 232% over 3 years indicates strong top-line expansion capability
- 5-year sales CAGR of 131% demonstrates sustained revenue momentum over a longer horizon
- 75% of analyst ratings (3 out of 4) recommend a Buy, suggesting some institutional optimism
- Compounded profit growth of 24% over 3 years shows the company has delivered some earnings improvement historically
- Market cap of Rs 18,695 Cr provides reasonable scale for a specialty pharma player to invest in R&D and distribution
- Price-to-book of 3.24x, while elevated, is not extreme for a healthcare company with high growth history
- Stock down 21% over 1 year may present a contrarian entry if turnaround materializes
Bear Case 8
- Negative PE ratio of -256.3x confirms the company is currently loss-making at the net income level
- Return on equity is negative at -2.39% over 3 years and -1% last year, destroying shareholder value
- Promoters have pledged 38.4% of holdings, signaling financial stress and risk of forced selling
- TTM profit growth of -161% indicates a sharp deterioration in earnings trajectory
- Debtor days of 177 indicate severe working capital stress and potential collection issues
- Low interest coverage ratio suggests debt servicing burden is consuming operating profits
- Zero dividend yield with no returns to shareholders despite Rs 18,695 Cr market cap
- Stock has declined 21% in 1 year while broader markets rallied, signaling underperformance
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 11d ago Positives 2
- Karnataka nod for Unit II May 16
OneSource received in-principle approval from Karnataka government for Unit II expansion under KIP 2025-30, aimed at boosting global manufacturing capacity.
- Q4FY26 revenue up 47% QoQ May 14
OneSource reported 47% quarter-on-quarter revenue growth in Q4 FY26 and published audited results in Financial Express and Lokmat under SEBI Regulation 47.
TL;DR: OneSource is firing on both growth levers — strong revenue momentum (47% QoQ in Q4FY26) and capacity expansion via Karnataka's Unit II approval under KIP 2025-30. No visible headwinds in recent news flow. The trend is clearly improving, with execution on manufacturing scale-up being the key monitorable in coming quarters.
Quarterly Results
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33.71 | 56.21 | 73.14 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 |
| Expenses | 72.22 | 66.71 | 75.94 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 |
| Operating Profit | -38.51 | -10.5 | -2.8 | 64.29 | 77.3 | 142 | 183 | 88.48 | 106 | 17.32 | 91.91 |
| OPM % | -114.24% | -18.68% | -3.83% | 22% | 23.14% | 36.14% | 42.85% | 27.04% | 28.34% | 5.97% | 21.46% |
| Other Income | -32.24 | -74.13 | 2.62 | -0.51 | -1.42 | -93.8 | 2.2 | 2.4 | 3.04 | -2.46 | 2.13 |
| Interest | 24.55 | 26.01 | 20.46 | 42.05 | 45.05 | 45.82 | 33.41 | 27.48 | 33.96 | 38.23 | 22.51 |
| Depreciation | 18.43 | 19.53 | 19.53 | 68.35 | 68.28 | 68.77 | 68.49 | 67.8 | 69.83 | 69.64 | 71.83 |
| PBT | -114 | -130 | -40.17 | -46.62 | -37.45 | -66.51 | 82.81 | -4.4 | 5.74 | -93.01 | -0.3 |
| Tax % | 0% | 0% | 0% | -88.1% | 12.36% | 3.53% | -18.95% | -95.68% | -82.58% | -4.63% | -1630% |
| Net Profit | -114 | -130 | -40.17 | -5.55 | -42.08 | -68.85 | 98.5 | -0.19 | 10.49 | -88.7 | 4.6 |
| EPS in Rs | — | — | — | — | — | -6.02 | 8.61 | -0.02 | 0.92 | -7.74 | 0.4 |
Profit & Loss
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 21 | 128 | 39 | 172 | 1,445 | 1,422 |
| Expenses | 93 | 132 | 199 | 235 | 978 | 1,117 |
| Operating Profit | -71 | -4 | -161 | -63 | 467 | 304 |
| OPM % | -334% | -3% | -415% | -37% | 32% | 21% |
| Other Income | 1 | -128 | -526 | -143 | -94 | 5 |
| Interest | 16 | 46 | 48 | 89 | 166 | 122 |
| Depreciation | 34 | 53 | 66 | 95 | 274 | 279 |
| PBT | -121 | -231 | -800 | -391 | -68 | -92 |
| Tax % | 0% | 0% | 0% | 0% | -73% | -20% |
| Net Profit | -121 | -231 | -800 | -391 | -18 | -74 |
| EPS in Rs | — | — | — | — | -1.57 | -6.44 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| Borrowings | 386 | 1,182 | 864 | 562 | 772 | 1,504 |
| Other Liabilities | 96 | 248 | 365 | 468 | 1,005 | 875 |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
| Fixed Assets | 633 | 1,231 | 1,361 | 863 | 6,118 | 6,233 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 314 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 |
| Other Assets | 195 | 722 | 314 | 356 | 1,305 | 1,648 |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,210 |
Cash Flow
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Operating | -118 | -416 | -163 | -107 | -68 | 9 |
| Investing | -207 | -692 | -68 | 511 | -201 | -495 |
| Financing | 381 | 1,162 | 118 | -391 | 412 | 359 |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO/OP | 164 | 10,397 | 108 | 169 | -13 | 6 |
Ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | — | 615 | 258 | 222 | 360 |
| Days Payable | 762 | — | 420 | 163 | 147 | 307 |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 | 180 | 230 |
| Working Capital Days | -2,392 | -1,331 | -6,745 | -877 | -58 | -29 |
| ROCE % | — | -3% | -12% | -12% | 6% | 1% |
Documents
1
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru. 4 May - Partner received Health Canada approval for generic semaglutide; OneSource will support commercial supply from Bengaluru.
2
Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (LODR), Regulations, 2015
7 May - Board meeting on May 13, 2026 to approve audited Q4 and FY2026 results; trading window closed from April 1. 7 May - Board meeting on May 13, 2026 to approve audited Q4 and FY2026 results; trading window closed from April 1.
3
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
7 May - Regarding earnings call to be held on May 13, 2026 7 May - Regarding earnings call to be held on May 13, 2026
4
General-Update
28 Apr - OneSource SPD facility received EU GMP certificate on April 27, 2026. 28 Apr - OneSource SPD facility received EU GMP certificate on April 27, 2026.
5
Announcement under Regulation 30 (LODR)-Press Release / Media Release
29 Apr - Dr. Reddy’s received Health Canada approval for generic Semaglutide Injection; OneSource will support commercial manufacturing. 29 Apr - Dr. Reddy’s received Health Canada approval for generic Semaglutide Injection; OneSource will support commercial manufacturing.
Frequently Asked Questions about OneSource Specialty Pharma Ltd
What does OneSource Specialty Pharma Ltd do?
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
...
Where is OneSource Specialty Pharma Ltd (ONESOURCE) listed?
OneSource Specialty Pharma Ltd is listed on the Indian stock exchanges. It is listed on NSE: ONESOURCE and BSE: 544292. You can view its live share price, financials, and ratios on Tapetide.
Which sector does OneSource Specialty Pharma Ltd belong to?
OneSource Specialty Pharma Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd has a market capitalisation of approximately ₹18073.47 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of OneSource Specialty Pharma Ltd?
The Price-to-Earnings (PE) ratio of OneSource Specialty Pharma Ltd is -242.70. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of OneSource Specialty Pharma Ltd?
Over the past 52 weeks, OneSource Specialty Pharma Ltd has traded between a low of ₹1,057 and a high of ₹2,231.9. This range helps investors understand the stock's price volatility and recent trading levels.
How can I research OneSource Specialty Pharma Ltd on Tapetide?
On Tapetide, you can view OneSource Specialty Pharma Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics[1]